Dare Bioscience (DARE) Projected to Post Earnings on Tuesday

Dare Bioscience (NASDAQ:DARE) is expected to be releasing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Dare Bioscience to post earnings of ($0.33) per share and revenue of $0.0270 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Thursday, March 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.42. The company had revenue of $1.02 million for the quarter, compared to analyst estimates of $0.75 million.

Dare Bioscience Trading Up 7.2%

Shares of NASDAQ:DARE traded up $0.22 on Tuesday, reaching $3.33. 1,903,135 shares of the company were exchanged, compared to its average volume of 350,236. Dare Bioscience has a 1-year low of $1.27 and a 1-year high of $9.19. The firm has a market cap of $48.53 million, a price-to-earnings ratio of -2.61 and a beta of 1.09. The company has a 50-day moving average of $1.78 and a 200-day moving average of $1.87.

Institutional Investors Weigh In On Dare Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in DARE. LPL Financial LLC purchased a new stake in shares of Dare Bioscience in the 4th quarter worth about $28,000. Raymond James Financial Inc. boosted its position in shares of Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Dare Bioscience in the 3rd quarter worth about $37,000. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.